Familial and Hereditary Forms of Primary Hyperparathyroidism.

Individuals with a familial predisposition to the development of parathyroid tumors constitute a small minority of all patients with primary hyperparathyroidism (PHPT). These familial syndromes exhibit Mendelian inheritance patterns and the main causative genes in most families have been identified. They include multiple endocrine neoplasia (MEN; types 1, 2A, and 4), hyperparathyroidism-jaw tumor (HPT-JT) syndrome, familial isolated hyperparathyroidism, familial hypocalciuric hypercalcemia (FHH), and neonatal severe PHPT. Each MEN type is associated with the various combinations of specific tumors. MEN1 is characterized by the occurrence of parathyroid, enteropancreatic, and pituitary tumors; MEN2A is characterized by medullary thyroid carcinoma and pheochromocytoma, and MEN4 is characterized by a pathological spectrum similar to that of MEN1 in association with tumors of the adrenal, kidney, and reproductive organs. HPT-JT is characterized by PHPT, ossifying fibromas of maxillary bones, kidney disease, and uterine neoplasias. The prompt diagnosis of these diseases is of great importance for planning appropriate surveillance of the mutant carriers and correct surgical management. The search for mutation is also useful for the identification of the family members who do not carry the mutation and can avoid unnecessary biochemical and instrumental evaluations. Surgery remains the treatment of choice in all familial forms except FHH.

[1]  C. Marcocci,et al.  Parathyroid carcinoma: a clinical and genetic perspective. , 2018, Minerva endocrinologica.

[2]  M. Adank,et al.  CDC73-Related Disorders: Clinical Manifestations and Case Detection in Primary Hyperparathyroidism , 2017, The Journal of clinical endocrinology and metabolism.

[3]  C. Stratakis,et al.  MEN4 and CDKN1B mutations: the latest of the MEN syndromes. , 2017, Endocrine-related cancer.

[4]  G. Gronchi,et al.  Multiple endocrine neoplasia syndrome type 1: institution, management, and data analysis of a nationwide multicenter patient database , 2017, Endocrine.

[5]  Julie C. Sapp,et al.  GCM2-Activating Mutations in Familial Isolated Hyperparathyroidism. , 2016, American journal of human genetics.

[6]  R. Thakker,et al.  Disorders of the calcium-sensing receptor and partner proteins: insights into the molecular basis of calcium homeostasis , 2016, Journal of molecular endocrinology.

[7]  G. Gronchi,et al.  Cinacalcet therapy in patients affected by primary hyperparathyroidism associated to Multiple Endocrine Neoplasia Syndrome type 1 (MEN1) , 2016, Endocrine.

[8]  Kathryn J. Rowland,et al.  Management of the Parathyroid Glands During Preventive Thyroidectomy in Patients With Multiple Endocrine Neoplasia Type 2. , 2015, Annals of surgery.

[9]  Douglas B. Evans,et al.  Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. , 2015, Thyroid : official journal of the American Thyroid Association.

[10]  E. Papini,et al.  Cinacalcet in the management of primary hyperparathyroidism: post marketing experience of an Italian multicentre group , 2013, Clinical endocrinology.

[11]  P. Chanson,et al.  Frequent large germline HRPT2 deletions in a French National cohort of patients with primary hyperparathyroidism. , 2013, The Journal of clinical endocrinology and metabolism.

[12]  F. Cetani,et al.  Genetic and Clinical Features of Multiple Endocrine Neoplasia Types 1 and 2 , 2012, Journal of oncology.

[13]  J. Bilezikian,et al.  Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). , 2012, The Journal of clinical endocrinology and metabolism.

[14]  M. Lei,et al.  The same pocket in menin binds both MLL and JUND but has opposite effects on transcription , 2012, Nature.

[15]  C. Marcocci,et al.  Clinical practice. Primary hyperparathyroidism. , 2011, The New England journal of medicine.

[16]  F. Raue,et al.  Inactivating calcium‐sensing receptor mutations in patients with primary hyperparathyroidism , 2011, Clinical endocrinology.

[17]  X. Hua,et al.  Menin represses tumorigenesis via repressing cell proliferation. , 2011, American journal of cancer research.

[18]  L. Barzon,et al.  The extent of parathyroidectomy for HRPT2-related hyperparathyroidism. , 2009, Surgery.

[19]  C. Marcocci,et al.  Re: Familial hyperparathyroidism: surgical outcome after 30 years of follow-up in three families with germline HRPT2 mutations. , 2008, Surgery.

[20]  H. Höfler,et al.  Germ-line mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans , 2006, Proceedings of the National Academy of Sciences.

[21]  W. Simonds,et al.  Familial Isolated Hyperparathyroidism: Clinical and Genetic Characteristics of 36 Kindreds , 2002, Medicine.